ZA976476B - Isolated peptides derived from mage-2 cytolytic t cells specific to complexes of peptide and hla-a2 molecules and uses thereof - Google Patents

Isolated peptides derived from mage-2 cytolytic t cells specific to complexes of peptide and hla-a2 molecules and uses thereof

Info

Publication number
ZA976476B
ZA976476B ZA976476A ZA976476A ZA976476B ZA 976476 B ZA976476 B ZA 976476B ZA 976476 A ZA976476 A ZA 976476A ZA 976476 A ZA976476 A ZA 976476A ZA 976476 B ZA976476 B ZA 976476B
Authority
ZA
South Africa
Prior art keywords
cytolytic
mage
hla
complexes
peptide
Prior art date
Application number
ZA976476A
Other languages
English (en)
Inventor
Cornelis J M Melief
M W Visseren
Sjoerd Van Der Burg
Pierre Van Der Bruggen
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Univ Leiden filed Critical Ludwig Inst Cancer Res
Publication of ZA976476B publication Critical patent/ZA976476B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA976476A 1996-07-25 1997-07-22 Isolated peptides derived from mage-2 cytolytic t cells specific to complexes of peptide and hla-a2 molecules and uses thereof ZA976476B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/687,226 US5686068A (en) 1994-03-24 1996-07-25 Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof

Publications (1)

Publication Number Publication Date
ZA976476B true ZA976476B (en) 1998-09-01

Family

ID=24759577

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA976476A ZA976476B (en) 1996-07-25 1997-07-22 Isolated peptides derived from mage-2 cytolytic t cells specific to complexes of peptide and hla-a2 molecules and uses thereof

Country Status (10)

Country Link
US (1) US5686068A (xx)
EP (1) EP0964868A4 (xx)
JP (1) JP2000516220A (xx)
KR (1) KR20000022423A (xx)
CN (1) CN1226897A (xx)
AU (1) AU710887B2 (xx)
CA (1) CA2261579C (xx)
NZ (1) NZ333606A (xx)
WO (1) WO1998004582A1 (xx)
ZA (1) ZA976476B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US6682731B1 (en) * 1994-03-24 2004-01-27 Ludwig Institute For Cancer Research Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US6087441A (en) * 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
WO1999065522A1 (en) * 1998-06-17 1999-12-23 Epimmune Inc. Hla binding peptides and their uses
EP1092154A2 (en) 1998-06-30 2001-04-18 The Rockefeller University Detection and modulation of cellular immunity to immune privileged antigens
WO2000000825A2 (en) * 1998-06-30 2000-01-06 The Rockefeller University Detection and modulation of cellular immunity to immune privileged antigens
CA2344972A1 (en) 1998-10-29 2000-05-11 Dana-Farber Cancer Institute, Inc. Cancer immunotherapy and diagnosis using universal tumor associated antigens, including htert
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
PT1282702E (pt) * 2000-05-10 2007-02-28 Ludwig Inst Cancer Res Polipéptidos imunogénicos codificados por minigenes mage e suas utilizações
AUPQ883200A0 (en) * 2000-07-18 2000-08-10 Telefonaktiebolaget Lm Ericsson (Publ) Telecommunication system and method of communicating protocol information
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
CA2449715A1 (en) * 2001-06-05 2002-12-12 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services, Centers For Disea Peptides for chlamydophila pneumoniae vaccine and diagnosis
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
EP1496939B1 (en) 2002-04-09 2007-08-15 Sanofi Pasteur Limited Modified cea nucleic acid and expression vectors
AU2003278036B2 (en) * 2002-10-22 2009-12-10 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
DK1620456T3 (da) 2003-04-18 2014-04-22 Biotech Synergy Inc Hla-a2 tumor-associerede antigen-peptider og præparater
US8562970B2 (en) * 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
DE69231621T2 (de) * 1991-08-26 2001-05-31 Epimmune, Inc. Hepatitis-B-Virus-Epitope mit HLA-reduzierte CTL-Respons
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
ATE342730T1 (de) * 1992-08-07 2006-11-15 Pharmexa Inc Hla bindepeptide und ihre verwendungen
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
AU7440196A (en) * 1995-10-12 1997-04-30 Chiron Corporation Baboon mage-3 homologs, dna encoding the homologs, and a process for their use

Also Published As

Publication number Publication date
CN1226897A (zh) 1999-08-25
CA2261579A1 (en) 1998-02-05
WO1998004582A1 (en) 1998-02-05
NZ333606A (en) 2000-04-28
EP0964868A4 (en) 2002-01-02
WO1998004582A8 (en) 1999-06-10
KR20000022423A (ko) 2000-04-25
CA2261579C (en) 2002-11-19
AU710887B2 (en) 1999-09-30
AU4045397A (en) 1998-02-20
US5686068A (en) 1997-11-11
EP0964868A1 (en) 1999-12-22
JP2000516220A (ja) 2000-12-05

Similar Documents

Publication Publication Date Title
ZA976476B (en) Isolated peptides derived from mage-2 cytolytic t cells specific to complexes of peptide and hla-a2 molecules and uses thereof
US5933819C1 (en) Prediction of relative binding motifs of biologically active peptides and peptide mimetics
GB2338237B (en) In vitro peptide or protein expression library
IL128529A0 (en) Anti-inflammatory peptides and uses thereof
HUP9901186A3 (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
PL330903A1 (en) Aqueous preparations of peptides
ZA952374B (en) Isolated peptides derived from MAGE antigen precursors which complex with HLA-A2 molecules and uses thereof
FI962619L (fi) Autoantigeenistä johdettuja uusia peptidejä autoimmuunitautien immunoterapiassa käyttöä varten
ZA977745B (en) Transdermal delivery of peptides
AU1159897A (en) Analogs of peptide yy and uses thereof
ZA97283B (en) Isolated tyrosinase derived peptides and uses thereof
EP0820295A4 (en) MODIFIED ARGININE OR LYSINE CONTAINING PROTEINS AND PEPTIDES
HUP9903961A3 (en) Tripeptide intermediates of antithrombotic azacycloalkylalkanoyl peptides
EP0923605A4 (en) Conjugated vaccines containing mucin
IL121329A (en) Pharmaceutical composition for the treatment of cancer comprising somatostatin2 and other peptides
NZ273815A (en) Peptide compositions for treating protein allergies or autoimmune diseases containing at least two isolated and purified peptides
EP1029034A4 (en) PROTEINS CONTAINING SIGNAL PEPTIDE AND THEIR USE
PL345958A1 (en) Novel peptides for use in immunotherapy of autoimmune diseases
IL148778A0 (en) Modified peptides and peptidomimetics for use in immunotherapy
GB2336844B (en) Anti-hiv peptides and proteins
ZA978220B (en) PTX-sensitive G proteins their preparation and use
IL127080A0 (en) The use of peptides derived from zona pelucida proteins for contraception and pharmaceutical compositions containing the same
AU5495500A (en) Decorin binding protein essential peptides and methods of use
GB2220938B (en) Use of pam enzyme in solid phase peptide synthesis
AU4611097A (en) Improvements in solid-phase synthesis of peptides and related compounds